Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)

Myocardial Infarct Clinical Trial

Official title:
A Single Center, Open, Randomized, Placebo-controlled Study Investigating the Safety of Administration of Ilomedin® in Addition to Standard Treatment in Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)

Status Completed

Clinical Trial Summary

Acute myocardial infarct patients with STEMI (ST-elevation on ECG) whom undergo a primary percutaneous cardiac intervention will following the standard treatment , received low dose of Ilomedin and to low dose of standard treatment for another 24 hours.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01179776
Study type	Interventional
Source	Thrombologic ApS
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	September 2010
Completion date	June 2011

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00237471` - Impact of Tight Glycaemic Control in Acute Myocardial Infarction	Phase 4
Active, not recruiting	`NCT02967965` - CARdioprotection in Myocardial Infarction
Completed	`NCT00560742` - Efficacy Study of Intramuscular or Intracoronary Injection of Autologous Bone Marrow Cells to Treat Scarred Myocardium	Phase 2
Completed	`NCT01264783` - Safety and Tolerability of RNS60 Given by IV to Healthy Subjects	Phase 1
Completed	`NCT01033617` - IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG	N/A
Completed	`NCT00338156` - Observational Study of the Remodelling Process Following Myocardial Infarct	N/A